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ABSTRACT 
The additive Axtra
®
 PHY 15 000 L is a liquid preparation of 6-phytase produced by a genetically modified strain 
of Trichoderma reesei. This product is intended for use as a zootechnical additive, functional group of 
digestibility enhancers, in feed for poultry and porcine species. The Panel on Additives and Products or 
Substances used in Animal Feed concluded that Axtra
®
 PHY 15 000 L does not give rise to safety concerns with 
regard to the genetic modification of the production strain. Neither the production strain nor its recombinant 
DNA was detected in the additive. The Panel concluded that the additive is safe for chickens and turkeys for 
fattening, laying hens, weaned piglets and sows at the maximum recommended dose (2 000 phytase units 
(FTU)/kg feed) and considered that this conclusion can be extended to other poultry categories/species and 
porcine categories/species at the same maximum dose. The Panel concluded that the use of Axtra
®
 PHY 
15 000 L as a feed additive gives rise to no concerns for consumers. This additive is not considered a dermal 
sensitiser but should be considered an irritant. Owing to the proteinaceous nature of its active substance, the 
additive is considered a potential respiratory sensitiser. The Panel concluded that the use of Axtra
® 
PHY 
15 000 L as a feed additive poses no risks to the environment. The efficacy studies submitted showed that the 
phytase present in Axtra
®
PHY 15 000 L is efficacious in chickens and turkeys for fattening, laying hens, piglets, 
pigs for fattening and sows at the dose of 250 FTU/kg feed. This conclusion can be extended to chickens reared 
for laying, turkeys reared for breeding, and to turkeys for breeding purposes, and extrapolated to minor poultry 
species for fattening and minor porcine species, at the same dose. 
© European Food Safety Authority, 2015 
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SUMMARY 
Following a request from the European Commission, the Panel on Additives and Products or 
Substances used in Animal Feed (FEEDAP) was asked to deliver a scientific opinion on the safety and 
efficacy of Axtra
®
 PHY 15 000 L (6-phytase) as a feed additive for poultry and pig species. 
The additive Axtra
®
 PHY 15 000 L is a liquid preparation of 6-phytase produced by a genetically 
modified strain of Trichoderma reesei. This product has not been previously authorised in the 
European Union and is intended for use as a zootechnical additive, functional group of digestibility 
enhancers, in feed for chickens for fattening or reared for laying, turkeys for fattening, reared for 
breeding or for breeding purposes, laying hens, minor poultry species, piglets (weaned), pigs for 
fattening, sows for reproduction, and minor porcine species. 
The Panel concluded that Axtra
®
 PHY 15 000 L does not give rise to safety concerns with regard to the 
genetic modification of the production strain. Neither the production strain nor its recombinant DNA 
was detected in the final product obtained from the production strain. 
Based on the tolerance trials provided, in which a 100-fold the maximum recommended dose was 
tolerated well by the animals, the Panel concluded that the additive is safe for chickens and turkeys for 
fattening, laying hens, weaned piglets and sows at the maximum recommended dose (2 000 phytase 
units (FTU)/kg). The Panel extended this conclusion to chickens reared for laying, to turkeys reared 
for breeding purposes or for breeding, and to pigs for fattening. The conclusion was also extrapolated 
to minor poultry and porcine species at the same maximum dose. 
The results obtained in genotoxicity and mutagenicity tests and in a sub-chronic oral toxicity study 
permitted the Panel to conclude that the use of Axtra
®
 PHY 15 000 L as feed additive gives rise to no 
concerns for consumers. 
The additive is not considered a dermal sensitiser but should be considered an irritant to eyes, skin and 
the respiratory tract. Owing to the proteinaceous nature of the active substance, the additive is 
considered a potential respiratory sensitiser. 
The Panel concluded that the use of Axtra
®
PHY 15 000 L as a feed additive poses no risks to the 
environment. 
The use of 6-phytase in feed should improve the assimilation of phosphorus and other minerals. The 
efficacy studies submitted showed that the phytase present in Axtra
® 
PHY 15 000 L is efficacious in 
chickens and turkeys for fattening, piglets, pigs for fattening and sows at the dose of 250 FTU/kg feed. 
For laying hens, two studies showed a significant effect at 250 FTU/kg and one at 300 FTU/kg (the 
lowest dose tested in the study). Considering that for all other species/categories, efficacy was 
demonstrated at 250 FTU/kg and that the difference between 250 and 300 FTU/kg is small, the Panel 
concluded that, for laying hens, the effective dose is also 250 FTU/kg. These conclusions were 
extended to chickens reared for laying, to turkeys reared for breeding and to turkeys for breeding 
purposes, and were extrapolated to minor poultry species for fattening and minor porcine species at the 
same dose. 
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BACKGROUND 70 
Regulation (EC) No 1831/2003
4
 establishes the rules governing the Community authorisation of 71 
additives for use in animal nutrition. In particular, Article 4(1) of that Regulation lays down that any 72 
person seeking authorisation for a feed additive or for a new use of a feed additive shall submit an 73 
application in accordance with Article 7. 74 
The European Commission received a request from Danisco UK Ltd
5
 for authorisation of the product 75 
Axtra
®
 PHY 15 000 L, 6-phytase, when used as a feed additive for chickens for fattening or reared for 76 
laying, turkeys for fattening, reared for breeding of for breeding purposes, laying hens, minor poultry 77 
species, piglets (weaned), pigs for fattening, sows for reproduction and minor porcine species 78 
(category: zootechnical additive; functional group: digestibility enhancers) under the conditions 79 
mentioned in Table 1. 80 
According to Article 7(1) of Regulation (EC) No 1831/2003, the Commission forwarded the 81 
application to the European Food Safety Authority (EFSA) as an application under Article 4(1) 82 
(authorisation of a feed additive or new use of a feed additive). EFSA received directly from the 83 
applicant the technical dossier in support of this application.
6
 According to Article 8 of that 84 
Regulation, EFSA, after verifying the particulars and documents submitted by the applicant, shall 85 
undertake an assessment in order to determine whether the feed additive complies with the conditions 86 
laid down in Article 5. The particulars and documents in support of the application were considered 87 
valid by EFSA as of 11 April 2014. 88 
The additive Axtra
®
 PHY 15000 L is a preparation of 6-phytase produced by a genetically modified 89 
strain of Trichoderma reesei that has not been previously authorised in the European Union. 90 
TERMS OF REFERENCE 91 
According to Article 8 of Regulation (EC) No 1831/2003, EFSA shall determine whether the feed 92 
additive complies with the conditions laid down in Article 5. EFSA shall deliver an opinion on the 93 
safety for the target animals, consumer, user and the environment and the efficacy of the product 94 
Axtra
®
 Phy 15 000 L (6-phytase), when used under the conditions described in Table 1. 95 
96 
                                                     
4 Regulation (EC) No 1831/2003 of the European Parliament and of the Council of 22 September 2003 on additives for use 
in animal nutrition. OJ L 268, 18.10.2003, p. 29. 
5 Danisco UK Ltd, PO Box 777, SN8 1XN, Marlborough, Wiltshire, UK.  
6 EFSA Dossier reference: FAD-2013-0049. 
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Table 1:  Description and conditions of use of the additive as proposed by the applicant  97 
Additive  15000 FTU/g 6-phytase 
Registration number/EC No/No 
(if appropriate) 
4axxx 
Category(ies) of additive Zootechnical additive 
Functional group(s) of additive Digestibility enhancer 
 
Description 
Composition, description 
Chemical 
formula 
Purity criteria 
(if appropriate) 
Method of analysis 
(if appropriate) 
Preparation of 6-phytase (EC 
3.1.3.26) produced by Trichoderma 
reesei 
Minimum 6-
phytase 
activity: 15000 
FTU/g 
Compliant EU feed 
hygiene law 
Colorimetric method 
 
Trade name (if appropriate) Axtra® PHY 15000 L 
Name of the holder of 
authorisation (if appropriate) 
Danisco (UK) Ltd. (trading as Danisco Animal Nutrition) 
 
Conditions of use 
Species or 
category of 
animal 
Maximum Age 
Minimum content Maximum content 
Withdrawal period 
(if appropriate) Units of activity/kg of complete feedingstuffs 
Chickens for 
fattening 
 
Chickens 
reared for 
laying 
 
Laying hens 
 
Turkeys for 
fattening 
 
Turkeys for 
breeding 
purposes 
 
Turkeys 
reared for 
breeding 
 
Weaned 
piglets 
 
Sows for 
reproduction 
 
Pigs for 
fattening 
 
Minor 
porcine 
species 
To slaughter age & 
weight 
 
24 weeks 
(point of lay) 
 
 
No maximum age 
 
To slaughter age & 
weight 
 
 
No maximum age 
 
 
30 weeks 
(point of lay) 
 
 
 
120 days 
 
 
No maximum age 
 
To slaughter age & 
weight 
 
 
No maximum age 
 
250 FTU/kg 2000 FTU/kg Not applicable 
Axtra
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Minor poultry 
species 
 
No maximum age 
 
 
Other provisions and additional requirements for the labelling 
Specific conditions or restrictions 
for use (if appropriate) 
Post-pellet application  
Specific conditions or restrictions 
for handling (if appropriate) 
R42, potential respiratory sensitizer. S22, do not breathe dust. 
Inhalation of enzyme aerosols or dust may cause allergic reactions in 
sensitized individuals. For user safety: Avoid direct contact and use in 
well-ventilated area. Breathing protection, safety glasses, and protective 
gloves/clothing are recommended 
Post-market monitoring 
(if appropriate) 
In compliance with EU feed hygiene legislation, traceability, HACCP, 
formal product/service complaints procedure, and product recall 
capability  
Specific conditions for use in 
complementary feedingstuffs 
(if appropriate) 
Final complete feed should contain 0.0167-0.133 kg Axtra® PHY 
15000 L per tonne feed (minimum 250 FTU 6-phytase/kg feed & 
maximum 2000 FTU 6-phytase/kg feed). 
 
Maximum Residue Limit (MRL)  
Marker residue 
Species or category of 
animal 
Target tissue(s) or 
food products 
Maximum content in 
tissues 
Not applicable Not applicable Not applicable Not applicable 
98 
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ASSESSMENT 99 
1. Introduction 100 
The additive Axtra
®
 PHY 15 000 L is a liquid preparation of 6-phytase (phytase; EC 3.1.3.26) 101 
produced by a genetically modified strain of Trichoderma reesei. This product has not previously been 102 
authorised in the European Union and is intended for use as a zootechnical additive, functional group 103 
of digestibility enhancers, in feed for chickens for fattening or reared for laying, turkeys for fattening, 104 
reared for breeding or for breeding purposes, laying hens, minor poultry species, piglets (weaned), 105 
pigs for fattening, sows for reproduction, and minor porcine species. The use of 6-phytase in feed 106 
should improve the assimilation of phosphorus and other minerals. 107 
2. Characterisation7 108 
2.1. Characterisation of the production organism 109 
The 6-phytase present in the additive under assessment is produced by fermentation of a genetically 110 
modified strain of T. reesei. The technical dossier contains detailed and sufficient information on the 111 
recipient microorganism, including aspects on the safety of the strain lineage, the origin and function 112 
of the different genetic elements introduced in the production strain, the genetic modification process 113 
and the genetic and phenotypic traits introduced. 114 
2.2. Manufacturing process 115 
The product is obtained by a multi-step process consisting in fermentation, concentration and 116 
purification steps. The resulting fermentation product is mixed and the final formulation is prepared 117 
with the addition of carriers and stabilisers. 118 
2.3. Characterisation of the additive 119 
Axtra
®
 PHY 15 000 L is a light brown liquid preparation with phytase as the main activity, which 120 
ensures a guaranteed minimum activity of 15 000 phytase units (FTU)
8
/g. Other activities present are 121 
xylanase, beta-glucanase and alpha-amylase activities. The batch-to-batch variation was studied in five 122 
batches and the mean value was 23 332 FTU/g, ranging from 21 800 to 24 500 FTU/g (coefficient of 123 
variation (CV) of 4.3 %).
9
 The additive contains the liquid fermentation product, sorbitol, sodium 124 
chloride, potassium sorbate, sodium benzoate and water. The additive has a specific gravity of 1.18– 125 
1.20 kg/L (at 20 °C), a pH of 5.3–5.5 and a viscosity of 5.61–6.08 cP (measured at 25 °C).10 126 
The additive was analysed for microbiological contaminants (eight batches),
11
 including total viable 127 
counts (< 78 colony-forming units (CFU)/mL), coliforms (< 1 CFU/mL), Escherichia coli and 128 
Salmonella spp. (not detected in 25 g). Three batches were investigated for their content of lead 129 
(< 5 mg/kg), cadmium and mercury (< 0.5 mg/kg), and arsenic (< 3 mg/kg). The levels of mycotoxins, 130 
including aflatoxins (< 5 µg/kg), ochratoxin (< 10 µg/kg), zearalenone (< 50 µg/kg), T2-toxin 131 
(< 25 µg/kg) and vomitoxin (< 0.5 µg/kg) were also determined in the same batches.
12
 Antibacterial 132 
activity was reported to be absent in three batches of the additive.
13 
The production strain was not 133 
detected in three batches of the additive. No recombinant DNA was detected in three batches of the 134 
final product tested by polymerase chain reaction.
 
135 
                                                     
7 This section has been edited following the confidentiality claims made by the applicant. 
8 One FTU is the amount of enzyme that releases 1 µmol of inorganic orthophosphate from a sodium phytate substrate per 
minute at pH 5.5 and 37 °C. 
9 Technical dossier/Section II/Annex II.2. 
10 Technical dossier/Section II/Annexes II.4, II.6 and II.9. 
11 Technical dossier/Section II/Annexes II.2, II.4 and II.6. 
12 Technical dossier/Section II/Annex II.4 and Supplementary information April 2015. 
13 Technical dossier/Section II/Annex II.4 and Supplementary information July 2015. 
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2.4. Stability and homogeneity 136 
The shelf lives of three batches of Axtra
®
 PHY 15 000 L were studied at 25 and 40 °C.
14
 The samples 137 
were kept in closed plastic containers for up to 12 months. The initial mean phytase content of the 138 
batches was 23 122 FTU/g and the mean recovery of phytase activity after 12 months was 78 % at 139 
25 °C and 71 % at 40 °C. 140 
The additive is intended to be applied by spraying onto pelleted feed. Three batches of the additive 141 
were sprayed onto a pelleted complete feed, based on maize and soya bean meal and containing a 142 
mineral and vitamin premixture, to provide 450 FTU/kg feed.
15
 Samples were kept in plastic 143 
containers at 25 or 40 °C for three months. Recovery values after three months were no different from 144 
the initial enzyme activity. In order to study the capacity of the additive to homogeneously distribute 145 
in feed, 10 sub-samples of each feed were analysed. The CV of the enzyme activity ranged from 5.8 to 146 
6.7 %. 147 
2.5. Conditions of use 148 
The additive is to be used in feed for chickens for fattening or reared for laying, turkeys for fattening 149 
or reared for breeding, laying hens, turkeys for breeding purposes and minor poultry species, weaned 150 
piglets, pigs for fattening, sows for reproduction, and minor porcine species at a minimum dose of 151 
250 FTU/kg. The maximum recommended dose is 2 000 FTU/kg feed for all species/categories. 152 
2.6. Evaluation of the analytical methods by the European Union Reference Laboratory 153 
(EURL) 154 
EFSA has verified the EURL report as it relates to the methods used for the control of the active 155 
substance in animal feed. The Executive Summary of the EURL report can be found in the Annex. 156 
3. Safety 157 
3.1. Safety aspects of the genetic modification16 158 
The recipient organism is considered safe. The introduced sequences give rise to no safety concerns. 159 
The product Axtra
®
 PHY 15 000 L does not give rise to any safety concerns with regard to the genetic 160 
modification of the production strain. 161 
3.2. Safety for the target species 162 
The test materials used in the tolerance studies were not the final product; for the tolerance group, a 163 
concentrated intermediate product (6-phytase concentrate, sodium benzoate and potassium sorbate) 164 
was used and, for the use level, a diluted version (three-fold diluted) of the final additive was used. 165 
The Panel considers that these test materials were adequate and will be referred in the studies below as 166 
Axtra
® 
PHY phytase. 167 
3.2.1. Chickens for fattening 168 
A total of 1 600 one-day-old chickens (Ross 308, male and female) were distributed in groups of 40 169 
birds, separated by sex, and allocated to one of four dietary treatments, resulting in 10 replicates per 170 
treatment.
17
 Starter and grower basal diets, based on wheat and soya bean meal and with a total 171 
phosphorus content of 0.51 % (starter) or 0.42 % (grower), were either not supplemented (negative 172 
control group) or supplemented with the Axtra
®
 PHY phytase to provide 2 000 FTU/kg feed (1× 173 
group) or 200 000 FTU/kg feed (100× group) (confirmed by analysis). A positive control diet with a 174 
total phosphorus content of 0.57 % (starter) or 0.52 % (grower) was also considered. Diets were 175 
offered ad libitum in pelleted form for 42 days. The feed intake, body weight and mortality were 176 
                                                     
14 Technical dossier/Section II/Annex II.21. 
15 Technical dossier/Section II/Annex II.22. 
16 This section has been edited following the confidentiality claims made by the applicant. 
17 Technical dossier/Section III/Annex III.1 and Supplementary information April 2015/Annex III.1.1. 
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recorded and the feed to gain ratio was calculated. Analysis of variance (ANOVA) was performed 177 
with the data including the effects of the dietary treatment, sex, and their interaction. The pen was the 178 
experimental unit. The mean values of the groups were compared with the least significant difference 179 
(LSD) test. Differences were considered significant at a level of at least P < 0.05. 180 
Mortality was within normal limits and was not treatment related (4.7, 5.4, 5.5 and 4.6 % for the 181 
negative control, 1×, 100× and positive control groups, respectively). Total feed intake of the birds 182 
were 4.9, 5.0, 5.0 and 5.0 kg feed/bird for the negative control, 1×, 100× and positive control groups, 183 
respectively, and were not affected by the dietary treatments. Final body weight values were 2.70, 184 
2.83, 2.88 and 2.82 kg for the negative control, 1×, 100× and positive control groups, respectively. 185 
The corresponding figures for the feed to gain ratio were 1.83, 1.81, 1.78 and 1.82, respectively. The 186 
supplementation of the diet with phytase at either dose resulted in a significantly higher mean body 187 
weight than the negative control diet; the 100× group had a significantly better feed to gain ratio. 188 
Feeding the birds with the phytase up to 100-fold the maximum dose did not have any negative effects 189 
on the performance parameters. Therefore, the FEEDAP Panel concludes that the product is safe for 190 
chickens for fattening at the maximum recommended dose. 191 
3.2.2. Safety for turkeys for fattening 192 
A total of 384 one-day-old female turkeys (BUT 9) were distributed in groups of 12 birds and 193 
allocated to one of four dietary treatments, resulting in eight replicates per treatment.
18
 Starter and 194 
grower basal diets, based on maize and soya bean meal and with a total phosphorus content of 0.62 % 195 
(starter) or 0.53 % (grower), were either not supplemented (negative control group) or supplemented 196 
with Axtra
®
 PHY phytase to 2 000 FTU/kg feed (1× group) or 200 000 FTU/kg feed (100× group) 197 
(confirmed by analysis). A positive control diet with a total phosphorus content of 0.79 % (starter) or 198 
0.77 % (grower) was also considered. Diets were offered ad libitum in pelleted form for 42 days. The 199 
feed intake, body weight and mortality were recorded and the feed to gain ratio was calculated. An 200 
ANOVA was performed with the data considering the pen as the experimental unit. Mean values of 201 
the groups were compared with the Fisher T-test. Differences were considered significant at a level of 202 
at least P < 0.05. 203 
One animal died (1× group) and another one was culled (100× group). Total feed intakes were 2.45, 204 
2.95, 2.95 and 2.73 kg feed/bird for the negative control, 1×, 100× and positive control groups, 205 
respectively; final body weight values were 1.58, 1.92, 1.92 and 1.72 kg and feed to gain ratio was 206 
1.57, 1.53, 1.55 and 1.58 for the negative control, 1×, 100× and positive control groups, respectively. 207 
The supplementation of the diet with Axtra
®
 PHY phytase resulted in a significantly higher feed intake 208 
and body weight, and better feed to gain ratio than the negative control diet. Feeding the birds with the 209 
phytase up to 100-fold the maximum dose, did not have negative effects on the performance 210 
parameters. Therefore, the FEEDAP Panel concludes that the product is safe for turkeys for fattening 211 
at the maximum recommended dose. 212 
3.2.3. Safety for laying hens 213 
A total of 400 21-week-old Isa brown hens were caged in groups of 10 hens and allocated to four 214 
dietary treatments, resulting in 10 replicates per treatment.
19
 A basal diet, based on maize and soya 215 
bean meal with a total phosphorus content of 0.44 %, was either not supplemented (negative control 216 
group) or supplemented with Axtra
®
 PHY phytase to provide 2 000 FTU/kg feed (1× group) or 217 
200 000 FTU/kg feed (100× group) (confirmed by analysis). A positive control diet with a total 218 
phosphorus content of 0.60 % content was also considered. Feed was offered in mash form for 219 
56 days. Body weight of the hens was measured at the beginning and at the end of the study. Health 220 
status, feed intake and laying performances were monitored/recorded throughout the study. Quality 221 
parameters, including yolk colour, albumen weight, egg shell thickness and shell index (% of egg 222 
weight) were measured in all eggs laid in a 24-hour period on weeks 4 and 8. At the end of the trial, 223 
                                                     
18 Technical dossier/Section III/Annex III.3. 
19 Technical dossier/Supplementary information April 2015/Annex III.14. 
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blood samples from 10 animals from each group were collected and haematological and biochemical 224 
parameters were determined.
20
 An ANOVA was performed with the data considering the cage as the 225 
experimental unit. Mean values of the groups were compared with the Fisher T-test. Differences were 226 
considered significant at a level of at least P < 0.05. 227 
Seven hens died, six from the negative control group and one from the 100× group. Daily feed intakes 228 
were 111, 110, 109 and 113 g for the negative control, 1×, 100× and positive control groups, 229 
respectively, laying intensities were 90.4, 91.8, 89.9 and 91.0 %, egg mass production values were 230 
28.0, 29.7, 28.7 and 29.6 kg/cage, feed to egg mass ratios were 2.07, 2.04, 2.08 and 2.12, and egg 231 
weights were 59.8, 59.0, 58.6 and 58.9 g/egg and were not affected by the addition of phytase. The 232 
body weight of the hens was not affected by the treatments. Egg quality parameter measurements 233 
showed some differences related to the dietary treatments, but these were not dose related. The results 234 
of the blood analyses showed a decrease in the number of heterophils in the phytase supplemented 235 
groups (16.1 × 10
3
 cells/µL in the non-supplemented vs. 8.4 × 10
3
 and 7.3 × 10
3
 cells/µL in the 1× and 236 
100× groups, respectively); however, values in the phytase-supplemented groups were not different to 237 
those in the positive control group (10.8 × 10
3
 cells/µL). Feeding the laying hens with the phytase up 238 
to 100-fold the maximum dose, did not have negative effects on the laying performance or egg quality, 239 
or on biochemical and haematological blood parameters. Therefore, the FEEDAP Panel concludes that 240 
the product is safe for laying hens at the maximum recommended dose. 241 
3.2.4. Safety for weaned piglets 242 
A total of 128 weaned male piglets (Landrace × Large White, 35–39 days old and initial mean body 243 
weight of 11.28 kg) were distributed into pens in groups of four piglets each and allocated to four 244 
dietary treatments, resulting in eight replicates per treatment.
21
 Weaner and starter diets, with a total 245 
phosphorus content of 0.48 % (weaner) and 0.41 % (starter), were either not supplemented (negative 246 
control group) or supplemented with Axtra
®
 PHY phytase to provide phytase at 2 000 FTU/kg of diet 247 
(1× group) and 200 000 FTU/kg of diet (100× group) (confirmed by analysis). A positive control diet 248 
with a total phosphorus content of 0.65 % (weaner) or 0.57 % (starter) was also considered. Before the 249 
start of the tolerance trial (28‒32 days of age), the piglets had a seven-day acclimatisation period in 250 
which the animals were given antibiotics via water for five days. Feed and water were available ad 251 
libitum over an experimental period of 42 days. The weaner diet (pelleted feed) was offered from day 252 
1 until day 14 and the starter diet (pelleted feed) from day 15 until day 42 of the experiment. Body 253 
weight and feed intake were recorded at days 0, 14 and 42, and average daily gain, average daily feed 254 
intake and feed to gain ratio were calculated. In addition, on day 42 of the experiment, blood samples 255 
were obtained from 10 piglets per treatment (randomly selected) for routine blood haematology and 256 
biochemistry.
22
 An ANOVA was performed with the data considering the pen as the experimental 257 
unit. Mean values of the groups were compared with the Tukey test. Differences were considered 258 
significant at a level of at least P < 0.05. 259 
A total of 13 piglets (four in the negative control group, eight in the 1× group and one in the 100× 260 
group) had to be individually treated with short courses of antibiotics for various reasons. Daily feed 261 
intakes were 0.98, 1.11, 1.04 and 1.09 kg for the negative control, 1×, 100× and positive control 262 
groups, respectively. The final body weight values were 35.8, 40.6, 39.7 and 40.3 kg, daily weight 263 
gains were 0.587, 0.698, 0.677 and 0.687 kg, and feed to gain ratios were 1.67, 1.59, 1.54 and 1.59 for 264 
                                                     
20 Including: calcium, phosphorus, creatinine, potassium, glucose, urea, bilirubin, lactate, fibrinogen, electrolytes (sodium, 
potassium chloride and calcium), total protein, albumin, globulin (and ratio of albumin to globulin), gamma-
glutamyltransferase (GT), alkaline phosphatase (AP), aspartate aminotransferase (AST), lactate dehydrogenase (LDH) 
and alanine aminotransferase (ALT), haemoglobin, mean corpuscular haemoglobin (MCH), mean corpuscular 
haemoglobin concentration (MCHC), mean corpuscular volume (MCV), haematocrit, red blood cell count, red blood cell 
distribution width, white blood cell count (including differential counts) and thrombocytes. 
21 Technical dossier/Supplementary information April 2015/Annex III.15. 
22 Including: fibrinogen, haemoglobin, mean corpuscular haemoglobin, MCHC, MCV, packed cell volume, platelets, red 
blood cell count and white blood cell counts (including differential counts), total protein, albumin, globulin, albumin to 
globulin ratio, urea, creatinine, total billirubin, glucose, inorganic phosphorus, chloride, potassium, sodium, calcium, AP, 
ALT, AST, GT and LDH activity. 
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the negative control, 1×, 100× and positive control groups, respectively. Body weights and daily 265 
weight gains in the 1× and 100× groups were higher than those in the negative control group, and the 266 
feed to gain ratio in the 100× group was better than in the negative control. Compared with the 267 
negative control diet, phytase supplementation at either dose increased inorganic phosphorus 268 
concentrations and decreased the alkaline phosphatase activity, supplementation at 100-fold increased 269 
the alanine aminotransferase (ALT) activity and decreased the mean corpuscular haemoglobin 270 
concentration. Since the values for the phytase-supplemented groups were no different from the values 271 
for the positive control group, these modifications are considered of no concern. Therefore, the 272 
supplementation of the diets with the phytase contained in Axtra
®
 PHY, at levels up to 100-fold the 273 
maximum recommended dose, did not have a negative effect on the parameters measured. The 274 
FEEDAP Panel concludes that the additive is safe for weaned piglets at the maximum recommended 275 
dose. 276 
3.2.5. Safety for pigs for fattening 277 
No specific study was provided to demonstrate the tolerance of pigs for fattening. The FEEDAP Panel 278 
considers that the conclusions reached with regard to piglets can be extended to pigs for fattening. 279 
3.2.6. Safety for sows for reproduction 280 
A total of 48 mature sows (Great York × Landrace) were housed in individual pens and, after equal 281 
distribution relative to parity (1–6), were allocated to four dietary treatments (12 sows per treatment).23 282 
Gestation and lactation diets, based on maize and soya bean meal with a total phosphorus content of 283 
0.42 % (gestation diet) or 0.51 % (lactation diet) were either not supplemented (negative control 284 
group) or supplemented with Axtra
®
 PHY phytase to provide 2 000 FTU/kg of diet (1× group) or 285 
200 000 FTU/kg of diet (100× group). Positive control diets with total phosphorus contents of 0.64 % 286 
(gestation) or 0.71 % (lactation) were also considered. Sows were under assessment for a full 287 
reproduction cycle (from weaning to weaning; a total of 143 days). Sows were fed, restrictively, a 288 
gestation diet (pelleted feed) from the start of the study until day 108 and a lactation diet (pelleted 289 
feed) from day 109 until the end of the experiment. Sow body weight and back-fat thickness were 290 
measured at weaning, at mating (start of experiment), at day 109 of gestation, at farrowing and at 291 
weaning (end of experiment). The feed intakes were recorded daily, and changes in body weight and 292 
back-fat thickness were calculated for several periods with respect to the above measurements. For 293 
each sow, gestation length, the number of piglets born (live and stillborn), piglet weight, mortality and 294 
daily weight gain during lactation, were recorded. An ANOVA was performed with the data 295 
considering the sow as the experimental unit. Mean values of the groups were compared with the LSD 296 
test. Differences were considered significant at a level of at least P < 0.05. 297 
No sows died during the experiment. Two sows (from the positive control and 100× groups) were 298 
treated with antibiotics because of low feed intakes and another sow (from the 100× group) was 299 
removed from the experiment because of an abortion. There were no significant treatment-related 300 
effects on sow feed intake, body weight or back-fat thickness, or any related changes throughout the 301 
study. The total number of live-born piglets (mean of 15 piglets per sow) was no different between 302 
treatments and the percentage of stillborn piglets was lower in the phytase supplemented groups than 303 
the negative control group (10.5%, 4.3 % and 2.5 % for the negative control, 1× and 100× groups, 304 
respectively). The number of piglets per litter after cross-fostering was 13.6 and at weaning was 11.7 305 
(mortality ≈ 14 %), and the daily weight gain of the piglets was 0.255 kg; no differences were found 306 
between treatments. The supplementation of the experimental diets with the phytase contained in 307 
Axtra
®
 PHY up to 100-fold the maximum recommended dose did not have a negative effect on the 308 
performance of sows for reproduction. Therefore, the FEEDAP Panel concludes that the additive is 309 
safe for sows. 310 
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3.2.7. Conclusions on the safety for target species 311 
The tolerance trials provided in chickens and turkeys for fattening, laying hens, weaned piglets and 312 
sows showed that the animals can tolerate doses up to 100-fold the maximum recommended dose of 313 
2 000 FTU/kg feed. Therefore, the FEEDAP Panel concludes that the additive is safe for these target 314 
species at the maximum recommended dose. 315 
The Panel considers that the conclusions reached for the chickens and turkeys for fattening can be 316 
extended to chickens reared for laying and turkeys reared for breeding, and the conclusions for laying 317 
hens can be extended to breeding hens at the same maximum dose. Similarly, the conclusions for 318 
weaned piglets can be extended to pigs for fattening at the same maximum dose. 319 
Based on the wide margin of safety shown, the conclusions can be extrapolated to minor poultry and 320 
porcine species at the same maximum dose. 321 
3.3. Safety for the consumer 322 
The 6-phytase concentrate that is used to formulate the final additive was used in the toxicological 323 
studies described below. 324 
3.3.1. Genotoxicity, including mutagenicity, studies 325 
3.3.1.1. Bacterial reverse mutation assay 326 
The potential of the concentrate to induce point mutations was assessed in the Salmonella 327 
Typhimurium strains TA98, TA100, TA102, TA1535 and TA1537 in accordance with OECD 328 
Guideline 471.
24
 The test material was tested by the preincubation method, both in the presence and 329 
absence of a metabolic activation system (Aroclor 1254-induced rat liver; S9-mix), up to a maximum 330 
concentration of 4 680 µg/mL. No biologically relevant increase in the number of revertant colonies 331 
was observed after treatment with the test material at any dose level, either in the presence or absence 332 
of metabolic activation. The positive controls performed as expected. 333 
3.3.1.2.  In vitro mammalian chromosome aberration test 334 
A study was carried out to evaluate the potential of the concentrate to induce structural changes in the 335 
chromosomes of human peripheral lymphocytes in the presence and absence of metabolic activation, 336 
in accordance with OECD Guideline 473.
25
 The cultures were treated with eight concentrations of the 337 
test material, diluted in cell culture medium, and the three highest concentrations (1 170, 2 340 and 338 
4 680 µg/mL) were analysed for their ability to induce chromosomal aberrations. Two independent 339 
tests were performed, with the following experimental schedules: (1) a three-hour treatment followed 340 
by a twenty-hour recovery period before cell harvesting, with and without S9-mix; (2) a 20-hour 341 
treatment followed by cell harvesting, without S9-mix, and the same schedule as test 1 with S9-mix. 342 
The concentration of S9 homogenate used in the second test was two-fold higher than the 343 
concentration used in the first test. 344 
A slight, but statistically significant, increase in the frequency of aberrant metaphases was observed in 345 
one culture treated at the intermediate concentration (2 340 µg/mL) without S9-mix in the first test, 346 
but it was not reproduced in the duplicate culture and was not dose related. In the second test without 347 
S9-mix, small increases in aberrations were observed at 1 170 and 2 340 µg/mL, but they were not 348 
dose related and were not confirmed in the duplicate culture. The other frequencies of aberrant 349 
metaphases were comparable with the negative controls. No increase was observed in any other 350 
experiment in the presence of S9-mix. The positive controls performed as expected. 351 
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3.3.2. Sub-chronic repeated dose oral toxicity study 352 
The study was conducted in compliance with OECD Guideline 408 (1998).
26
 The test material was 353 
diluted with sterile water to give doses of 0, 3.84, 9.6 or 28.8 mg/mL of total protein. Dilutions were 354 
prepared weekly and concentrations were confirmed by analysis of frozen samples from weeks 1, 7 355 
and 13. Groups of 10 Sprague–Dawley (Ntac:SD) rats were given test material by gavage at a dose of 356 
0, 19.2, 48 or 144 mg total protein/kg body weight per day. Doses were administered in a constant 357 
volume of 5 mL/kg body weight. Animals were inspected twice daily and examined in detail weekly. 358 
On one occasion towards the end of the study, all animals were examined for reactivity, grip strength 359 
and motor activity. Body weight, food and water intake were recorded weekly throughout the study. 360 
Ophthalmoscopy was conducted on all animals prior to the start of the study and on all animals from 361 
the control and high dose groups during the last week of treatment. Blood samples were taken on day 362 
30 or 31 and at the end of the treatment period and were subject to haematological
27
 and clinical 363 
chemistry
28
 examinations. Urine samples collected from all groups during the final week of treatment 364 
were examined.
29
 All animals were subject to necropsy, by which all organs were examined 365 
macroscopically and samples were preserved for histological examination. The following organs were 366 
weighed as appropriate: adrenals, brain, epididymis, heart, kidneys, liver, ovaries, spleen, testes, 367 
thymus and uterus. 368 
There were no treatment-related effects on observations, body weight, food intake, water intake, 369 
ophthalmoscopy or urinalysis. Some differences were seen between groups in the results of the 370 
haematological and clinical chemistry examinations but these were either restricted to one sex only, 371 
seen in the low or middle dose level only, or not seen consistently throughout the study. Therefore, 372 
none of these findings was considered to be attributable to treatment. There were no treatment-related 373 
statistically significant differences in organ weights between treated and control animals. A slight 374 
trend towards an increase in testis weight with dose was observed, but was not considered to be related 375 
to treatments as there was no associated histopathology. There were no treatment-related effects on the 376 
incidence or severity of any lesions in any treated group. 377 
3.3.3. Conclusions on the safety for the consumer 378 
The results obtained with 6-phytase concentrate used to formulate the additive in the genotoxicity 379 
studies and in the sub-chronic oral toxicity study do not indicate any reason for concern for consumer 380 
safety arising from the use of the product as a feed additive. 381 
3.4. Safety for the user 382 
The studies provided in this section were performed either with the 6-phytase concentrate that is used 383 
to formulate the final additive or with an intermediate product (referred to as “6-phytase 384 
intermediate”) that consists of the enzyme concentrate, sodium benzoate and potassium sorbate. 385 
3.4.1. Effects on the respiratory system 386 
The acute inhalation toxicity of “6-phytase intermediate” was investigated by exposing a group of five 387 
male and five female Sprague–Dawley rats to an aerosol atmosphere using a chamber concentration of 388 
5.0 mg/L of the test material.
30
 Based on the results, the test material is classified as non-toxic by 389 
inhalation. 390 
                                                     
26 Technical dossier/Section III/Annex 9. 
27 Including: haemoglobin, red blood cell counts, haematocrit, MCV, MCH, MCHC, white blood cell count (including 
differential counts), platelet counts, activated partial thromboplastin time, prothrombin time and fibrinogen. 
28 Including: AST, ALT AP, GT, bilirubin, cholesterol, triglycerides, urea, creatinine, glucose, sodium, potassium, calcium, 
magnesium, inorganic phosphorus, chloride, total protein, albumin and globulin (and the ratio of globulin to albumin). 
29 Including: volume, sodium, potassium, chloride, specific gravity, pH, colour, protein, leucocytes, nitrite, blood, glucose, 
ketones, bilirubin and uribilinogen. 
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Because of the proteinaceous nature of the active substance, the additive should be considered a 391 
potential respiratory sensitiser. 392 
3.4.2. Effects on skin and eyes 393 
The acute dermal irritant potential of the 6-phytase concentrate was investigated in three rabbits, in 394 
accordance with OECD Guideline 404.
31
 Based on the results, the test material is classified as non- 395 
irritant to skin. 396 
The eye irritancy of the 6-phytase concentrate was investigated in accordance with the method 397 
recommended in OECD Guideline 405.
32
 On the basis of the results, the test material is classified as 398 
non-irritant to eyes. 399 
A study was performed to assess the skin sensitisation potential of the “6-phytase intermediate” in the 400 
CBA/Ca mouse strain after topical application to the dorsal surface of the ear, in accordance with 401 
OECD Guideline 429.
33
 The stimulation index for the three concentrations of the test material was 402 
always lower than 3; therefore, the test material is considered to be a non-sensitiser under the tested 403 
conditions. 404 
3.4.3. Conclusions on the safety for the user 405 
The 6-phytase concentrate or an intermediate product were tested. The results showed that the test 406 
materials are not toxic by inhalation, not irritant to skin or eyes and not dermal sensitisers. The Panel 407 
considers that the substances added during the formulation of the additive are not likely to contribute 408 
to sensitisation, but the presence of sodium chloride may influence the irritant properties. Therefore, 409 
the additive is not considered a dermal sensitiser but should be considered a potential irritant to skin, 410 
eyes and the respiratory tract. 411 
Because of the proteinaceous nature of the active substance, the additive is considered a potential 412 
respiratory sensitiser. 413 
3.5. Safety for the environment 414 
Neither the production strain nor its recombinant DNA was detected in the final product. The final 415 
product does not pose any environmental safety concerns associated with the genetic modification of 416 
the production strain. 417 
The active substance of the additive is a protein, and as such will probably be degraded/inactivated 418 
during passage through the digestive tract of animals or in the environment. Therefore, no risks to the 419 
environment are expected and no further environmental risk assessment is required. 420 
4. Efficacy 421 
None of the test materials used in the efficacy studies was the final product, but were preparations with 422 
a lower enzyme activity (two- to three-fold lower). The Panel considers these test materials to be 423 
adequate and will refer to these materials in the studies below as Axtra
®
 PHY phytase. 424 
In all of the trials, differences were considered statistically significant at a level of at least P < 0.05. 425 
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4.1. Chickens for fattening 426 
4.1.1. Trial 1 427 
A digestibility/balance trial was performed with a total of 153 male chickens (Ross).
34
 During their 428 
first week of life, the birds were fed a common diet (total phosphorus content of 0.84 %), then the 429 
birds were fed one of the three experimental diets. Until day 14, the birds were kept in three pens of 17 430 
birds per treatment. On day 14, a total of 144 birds were randomly selected and transferred, in groups 431 
of four birds, to cages, resulting in 12 replicates per treatment. A basal diet, based on wheat and soya 432 
bean meal with a total phosphorus content of 0.73 % (calcium 1.1 %), was either not supplemented 433 
(negative control) or supplemented with Axtra
®
 PHY phytase to provide 250 FTU/kg feed (confirmed 434 
by analysis). A positive control diet was also considered (total phosphorus content 0.84 %; calcium 435 
1.1 %). Feed was offered ad libitum in pelleted form and contained titanium dioxide as an external 436 
marker. The performance of the birds was monitored throughout the study. The balance study 437 
consisted of three days of adaptation to the cage (days 14 to 17), and four days of excreta collection 438 
and feed intake measurements (days 18 to 21). Birds were weighed on days 0, 7, 14 and 21 439 
(individually identified). On day 21, birds were slaughtered and ileal contents were collected and 440 
pooled per cage. Ileal contents, excreta and feed samples were analysed in order to study the 441 
digestibility/utilisation of dry matter (data not shown), phosphorus and calcium, as well as the energy 442 
content (not analysed in ileal contents, data not shown). An ANOVA was performed with the data and 443 
the comparison of the group means was performed using a Tukey test. 444 
Two birds died in the pre-experimental phase. Ileal digestibility and retention of phosphorus were 445 
significantly higher in the group fed the phytase at 250 FTU/kg feed than in the group fed the negative 446 
control diet (Table 2). 447 
Table 2:  Effect of Axtra® PHY on the ileal digestibility and retention of dietary phosphorus and 448 
calcium  449 
Treatment Ileal digestibility (%) Retention (%) 
Phosphorus Calcium Phosphorus Calcium 
Negative control 75.3
b
 76.4 56.8
b
 56.4
b
 
250 FTU/kg 83.1
a
 78.1 63.9
a
 64.8
a
 
Positive control 74.9 75.7 55.7
b
 64.0
a
 
a,b Values within one column with different superscripts are significantly different (P < 0.05). 450 
4.1.2. Trial 2 451 
A balance trial was performed with a total of 160 male chickens (Ross 308).
35
 During their first week 452 
of life, the birds were fed a commercial diet. From days 7 to 21, the birds were distributed among 453 
raised floor pens in groups of four birds and allocated to one of the five dietary treatments (resulting in 454 
eight replicates per treatment). A basal diet, based on maize and soya bean meal with a total 455 
phosphorus content of 0.49 % (calcium 0.95 %), was either not supplemented (negative control) or 456 
supplemented with Axtra
®
 PHY phytase to provide 250, 500 or 1 000 FTU/kg feed (confirmed by 457 
analysis). A positive control diet was also considered (total phosphorus content 0.65 %; calcium 458 
0.92 %). Feed was offered ad libitum in mash form and contained titanium dioxide as an external 459 
marker. The performance of the birds was monitored throughout the study. The birds were weighed on 460 
days 0, 7 and 21. The balance study consisted of 10 days of adaptation (days 8 to 18), and three days 461 
of total excreta collection and feed intake measurements (days 19 to 21). Excreta and feed samples 462 
were analysed in order to study the utilisation of dry matter, phosphorus, calcium and nitrogen (data 463 
not shown), as well as the energy content (data not shown). ANOVA was performed with the data, 464 
considering the pens as the experimental unit, and the comparison of the means was performed using a 465 
Tukey test. 466 
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Two animals from the 1 000 FTU/kg feed group died. A higher retention of phosphorus was found in 467 
birds fed the diet supplemented with 250 FTU/kg feed or more than in the birds fed the negative 468 
control diet (Table 3). 469 
Table 3:  Effect of Axtra® PHY on the retention of dietary phosphorus and calcium  470 
Treatment Phosphorus (%) Calcium (%) 
Negative control 46.8
b
 47.5
b
 
250 FTU/kg 61.5
a
 62.1
ab
 
500 FTU/kg 60.2
a
 63.8
a
 
1 000 FTU/kg 64.5
a
 62.5
ab
 
Positive control 53.7
ab
 63.4
a
 
a,b Values within one column with different superscripts are significantly different (P < 0.05). 471 
4.1.3. Trial 3 472 
A digestibility/balance trial with measurements of bone mineralisation was performed with a total of 473 
288 male chickens (Ross 308).
36
 Until day 5 of their lives, the birds were housed in a floor pen and 474 
were fed a commercial diet. On day five, the birds were transferred to 18 cages, in groups of 16 birds 475 
per cage, and were allocated to one of the three dietary treatments, resulting in six replicates per 476 
treatment. A basal diet, based on wheat and soya bean meal with a total phosphorus content of 0.43 % 477 
(calcium 0.70 %), was either not supplemented (negative control) or supplemented with Axtra
®
 PHY 478 
phytase to provide 250 FTU/kg feed (confirmed by analysis). A positive control diet was also 479 
considered (total phosphorus content 0.61 %; calcium 0.80 %). Feed was offered ad libitum in pelleted 480 
form and contained titanium dioxide as an external marker. The birds were weighed on days 5 and 21, 481 
and feed intake was measured throughout the study. The balance study consisted of three days of 482 
excreta collection and feed intake measurements (days 18 to 20). On day 21, the birds were 483 
slaughtered and ileal contents were collected and pooled per cage; the left tibia was collected from 484 
four birds per cage. Ileal contents, excreta and feed samples were analysed in order to study the 485 
digestibility/utilisation of dry matter, phosphorus and calcium. Bones were dried, defatted and then ash 486 
content was determined. An ANOVA was performed with the data, considering the pen as the 487 
experimental unit, and the comparison of the group means was performed using a Tukey test. 488 
Phosphorus ileal digestibility, phosphorus retention and tibia ash content were higher in the group fed 489 
the phytase at 250 FTU/kg feed than in group fed the negative control diet (Table 4). 490 
Table 4:  Effect of Axtra® PHY on the apparent ileal digestibility and the retention of phosphorus 491 
and calcium, and on the tibia ash content  492 
Treatment Ileal digestibility (%) Retention (%) Tibia ash content 
(g/kg DM fat free) 
Phosphorus Calcium Phosphorus Calcium 
Negative control 59.1
b
 68.1
a
 56.7
b
 44.9
b
 380
c
 
250 FTU/kg 65.5
a
 64.0
a
 64.0
a
 46.7
b
 419
b
 
Positive control 55.8
c
 48.3
b
 53.0
b
 52.2
a
 465
a
 
a,b,c Values within one column with different superscripts are significantly different (P < 0.05). 493 
In three trials, the supplementation of diets with Axtra
®
PHY at 250 FTU/kg resulted in a significant 494 
improvement in phosphorus retention in chickens for fattening. 495 
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4.2. Turkeys for fattening 496 
4.2.1. Trial 1 497 
A balance trial with measurements of bone mineralisation was performed with 450 one-day-old male 498 
turkeys (BUT Big 6).
37
 Until day seven of life, the birds were housed in eight floor pens and fed a diet 499 
with a total phosphorus content of 0.86 %. At day seven, the turkeys were distributed among 45 cages 500 
in groups of 10 and allocated to five dietary treatments, resulting in nine replicates per treatment. A 501 
basal diet, based on maize and soya bean meal and with a total phosphorus content of 0.63 % (calcium 502 
0.99 %), was either not supplemented (negative control) or supplemented with Axtra
®
 PHY phytase to 503 
provide 250, 1 000 or 2 000 FTU/kg feed (confirmed by analysis). A positive control was also 504 
considered (total phosphorus content 0.78 %; calcium 1.16 %). Feed was offered ad libitum in pelleted 505 
form and contained hydrochloric acid (HCl)-insoluble ash as an external marker. The birds were 506 
weighed on days 7 and 29, and feed intake was measured throughout the study. The balance study 507 
consisted of four days of excreta collection and feed intake measurements (days 25 to 29). At the end 508 
of the study, the birds were slaughtered and the left tibia was collected for four birds per cage. Excreta 509 
and feed samples were analysed in order to study the utilisation of dry matter, nitrogen, energy (data 510 
not shown), phosphorus and calcium. Bones were dried, defatted and then ash and phosphorus 511 
contents were determined. An ANOVA was performed with the data, considering the cage as the 512 
experimental unit, and the comparison of the group means was performed using a Tukey test. 513 
The mortality values were 3.3, 4.4, 1.1, 1.1 and 6.7 % for the groups fed the negative control, 514 
250 FTU/kg, 1 000 FTU/kg, 2 000 FTU/kg and positive control diets, respectively, and were not 515 
statistically different among treatments. The results showed that groups fed a diet supplemented with 516 
phytase (250 FTU/kg or more) had significantly higher phosphorus retention, tibia ash and phosphorus 517 
content than in group fed the negative control diet (Table 5). 518 
Table 5:  Effect of Axtra® PHY on the retention of phosphorus and calcium and on the tibia ash and 519 
phosphorus content  520 
Treatment Retention (%) Tibia content  
(g/kg DM fat free) 
Phosphorus Calcium Ash Phosphorus 
Negative control 47.8
c
 40.9
c
 333
c
 59
c
 
250 FTU/kg 58.4
b
 50.5
b
 389
b
 69
b
 
1 000 FTU/kg 68.7
a
 61.6
a
 443
a
 81
a
 
2 000 FTU/kg 66.5
a
 59.4
a
 447
a
 80
a
 
Positive control 47.6
c
 43.1
c
 401
b
 71
b
 
a,b,c Values within one column with different superscripts are significantly different (P < 0.05). 521 
4.2.2. Trial 2 522 
A digestibility/balance trial with measurements of bone mineralisation was performed with a total of 523 
400 one-day-old male turkeys (Nicholas).
38
 Birds were distributed into 40 cages in groups of 10 birds 524 
and allocated to one of the five dietary treatments (representing eight replicates per treatment). A basal 525 
diet, based on maize and soya bean meal with a total phosphorus content of 0.74 % (calcium 1.36 %) 526 
was either not supplemented (negative control) or supplemented with Axtra
®
 PHY phytase to provide 527 
250, 500 or 1 000 FTU/kg feed (confirmed by analysis). A positive control was also considered (total 528 
phosphorus content 0.92 %; calcium 1.66 %). Feed was offered ad libitum in pelleted form and 529 
contained HCl-insoluble ash as an external marker. The birds were weighed on days 0, 7, 14, 21 and 530 
27 or 28, and feed intake was measured throughout the study. The balance study consisted of three 531 
days of excreta collection and feed intake measurements (days 22 to 24). Excreta and feed samples 532 
were analysed in order to study the retention of phosphorus and calcium. An ANOVA was performed 533 
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with the data, considering the cage as the experimental unit, and the comparison of the group means 534 
was performed using a Tukey test. 535 
The addition of phytase to the diets resulted in a significantly higher phosphorus digestibility/retention 536 
at 250 FTU/kg feed or above (Table 6). 537 
Table 6:   Effect of Axtra® PHY on the retention of phosphorus  538 
Treatment Retention (%) 
Phosphorus Calcium 
Negative control 41.8
c
 25.6
b
 
250 FTU/kg 50.6
b
 40.1
a
 
500 FTU/kg 60.3
a
 37.2
a
 
1 000 FTU/kg 58.7
a
 45.6
a
 
Positive control 34.4
c
 14.8
c
 
a,b,c Values within one column with different superscripts are significantly different (P < 0.05). 539 
4.2.3. Trial 3 540 
A digestibility trial with measurements of bone mineralisation was performed with 288 one-day-old 541 
male turkeys (BUT Big 6).
39
 Until day five of life, the birds were housed in eight floor pens and fed a 542 
commercial diet. At day five, the turkeys were distributed among 18 cages in groups of 16 and 543 
allocated to three dietary treatments, resulting in six replicates per treatment. A basal diet, based on 544 
maize and soya bean meal and with a total phosphorus content of 0.56 % (calcium 0.80 %), was either 545 
not supplemented (negative control) or supplemented with Axtra
®
 PHY phytase at 250 FTU/kg feed 546 
(confirmed by analysis). A positive control was also considered (total phosphorus content 0.75 %, 547 
calcium 0.90 %). Feed was offered ad libitum in pelleted form and contained titanium dioxide as an 548 
external marker. The birds were weighed at the beginning and at the end of the study, and feed intake 549 
was measured throughout the study. At the end of the study (day 21), the birds were slaughtered and 550 
ileal samples from all animals (pooled per cage) and the left tibia from four birds per cage were 551 
collected. Ileal and feed samples were analysed in order to study the utilisation of dry matter (data not 552 
shown), phosphorus and calcium. Bones were dried, defatted and then ash content was determined. An 553 
ANOVA was performed with the data, considering the cage as the experimental unit, and the 554 
comparison of the group means was performed using a Tukey test. 555 
Apparent ileal digestibility of phosphorus and tibia ash content were significantly higher in the group 556 
fed the diet supplemented with phytase at 250 FTU/kg than in the negative control group (Table 7). 557 
Table 7:  Effect of Axtra® PHY on the ileal digestibility of phosphorus and calcium and on the tibia 558 
ash content  559 
Treatment Ileal digestibility (%) Tibia ash content (g/kg DM fat 
free) Phosphorus Calcium 
Negative control 49.8
b
 51.2 363
c
 
250 FTU/kg 59.5
a
 56.5 414
b
 
Positive control 59.6
a
 53.2 480
a
 
a,b,c Values within one column with different superscripts are significantly different (P < 0.05). 560 
In three trials, the supplementation of diets with the additive at the dose of 250 FTU/kg resulted in a 561 
significant improvement of phosphorus utilisation in turkeys for fattening. 562 
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4.3. Laying hens 563 
A total of five trials were assessed. Two
40
 of these studies did not meet the necessary requirements 564 
because either the retention of phosphorus was not measured or the performance of the hens was not 565 
reported; consequently, these two studies were not considered further in the assessment. Two short- 566 
term trials and one long-term trial were considered. 567 
4.3.1. Trial 1 568 
A balance trial was performed with a total of 72 21-week-old laying hens (Hy-line) (90 % laying 569 
rate).
41
 The trial comprised three dietary treatments with 12 replicates of two hens each (two 570 
hens/cage). From week 21 to week 27 of life, hens were fed with a basal diet, based on wheat and soya 571 
bean meal with a total phosphorus content of 0.34 % (calcium 3.4 %), that was either not 572 
supplemented (negative control) or supplemented with Axtra
®
 PHY phytase to provide 250 FTU/kg 573 
feed (confirmed by analysis). A positive control was also considered (total phosphorus content 0.65 %; 574 
calcium 3.6 %). Feed was offered ad libitum in mash form. The balance study consisted of three days 575 
of total excreta collection during the last week of the trial. Feed intake was measured during the 576 
excreta collection period. Laying performance (laying rate, egg weight and feed-to-gain ratio) and feed 577 
intake were measured throughout the study. Hens were weighed at the start and at the end of the trial. 578 
An ANOVA was performed with the data, considering the cage as the experimental unit, and the 579 
comparison of the group means was performed using a Tukey test. 580 
Phosphorus retention (measured in the excreta) was significantly higher in the group fed the diet 581 
supplemented with 250 FTU/kg feed than in the group fed the negative control diet. The results also 582 
showed that the laying rate, egg mass production and feed intake were not different in the group fed 583 
the phytase at 250 FTU/kg, as compared with the negative control, between weeks 21 and 27. 584 
Table 8:  Effect of Axtra® PHY on the retention of phosphorus and calcium1 585 
Treatment Phosphorus (%) Calcium (%) 
Negative control 21.8 
b
 40.8 
b
 
250 FTU/kg 39.9 
a
 51.5 
a
 
Positive control 27.1 
b
 44.9
ab
 
1 Retention values do not consider the P in the eggs. 586 
a,b Values within one column with different superscripts are significantly different (P < 0.05). 587 
4.3.2. Trial 2 588 
A balance study was performed with 36 24-week-old ISA Brown hens that were individually caged 589 
and allocated to one of the two dietary treatments, resulting in 18 replicates per treatment.
42
 A basal 590 
diet, based on wheat, barley, maize and soya bean meal with a total phosphorus content of 0.34 % 591 
(calcium 3.9 %), was either not supplemented (negative control) or supplemented with Axtra
®
 PHY 592 
phytase to provide 250 FTU/kg feed (confirmed by analysis). Experimental feeds were offered for 28 593 
days in mash form and contained chromium oxide as an external marker. The body weight of the hens 594 
was measured at the start and at the end of the trial. Feed intake was recorded weekly, egg production 595 
and egg weight were measured daily, and egg mass and feed efficiency were calculated weekly. The 596 
collection of excreta samples was carried out for three days (days 26 to 28) and these were analysed 597 
for phosphorus and calcium. All eggs laid on days 25 to 27 were collected, pooled per bird and 598 
analysed for phosphorus content. At the end of the study, all of the hens were slaughtered and the left 599 
tibia collected for the determination of ash, calcium and phosphorus contents. An ANOVA was 600 
performed with the data, considering the cage as the experimental unit, and the comparison of the 601 
group means was performed using a Tukey test. 602 
                                                     
40 Technical dossier/Section IV/Annexes IV.4 and IV.5. 
41 Technical dossier/Section IV/Annexes IV.6 and Supplementary information April 2015/Annex. 
42 Technical dossier/Supplementary information April 2015/Annex IV.20. 
Axtra
®
PHY for poultry and pigs 
 
EFSA Journal 2015;13(11):4275 21 
The retention of phosphorus, measured in the excreta, and the tibia ash/phosphorus contents were 603 
significantly increased by the phytase (Table 9). The phosphorus content of eggs was not modified by 604 
the treatments. During the four weeks of the trial, no differences were found between the treatments 605 
with regard to feed intake, egg production (98 %) or egg weight (64 g). 606 
Table 9:  Effect of Axtra® PHY retention of phosphorus and calcium, egg phosphorus content and 607 
the tibia ash content  608 
Treatment Retention (%) Egg 
phosphorus 
content (%) 
Tibia (% as is) 
Phosphorus Calcium Ash Phosphorus 
Negative control 30.5
b
 63.9
b
 0.131 22.8
b
 3.9
b
 
250 FTU/kg 46.2
a
 70.7
a
 0.133 24.2
a
 4.2
a
 
a,b Values within one column with different superscripts are significantly different (P < 0.05). 609 
4.3.3. Trial 3 610 
A performance trial was carried out with a total of 240 23-week-old ISA Brown hens. From week 23 611 
to week 26 the egg production was monitored. On week 26 and considering the egg production of the 612 
previous three weeks, the hens were distributed to 48 cages in groups of five hens and allocated to one 613 
of the three experimental treatments, resulting in 16 replicates per treatment.
43
 From week 26 to week 614 
60, hens were fed with two basal diets (changed during week 43), based on maize and soya bean meal 615 
with a total phosphorus content of 0.42 and 0.40 %, respectively (calcium 3.5 and 3.7 %, respectively), 616 
that were either not supplemented (negative control) or supplemented with Axtra
®
 PHY phytase to 617 
provide 300 FTU/kg feed (confirmed by analysis). A positive control diet was also considered (total 618 
phosphorus content 0.60 and 0.57 %, and calcium 3.6 and 3.8 %, respectively). Feed was offered ad 619 
libitum in mash form for 34 weeks. The health of the laying hens was monitored daily. Egg production 620 
was recorded daily, all eggs produced in one day were weighed every 14 days and total egg mass was 621 
calculated. Feed intake was monitored throughout the study and the body weight of the hens was 622 
recorded at the beginning and at the end of the trial. Feed to egg mass ratio was calculated. An 623 
ANOVA was performed with the data and the comparison of the group means was performed using a 624 
Tukey test. 625 
Nine hens in total died, four from the positive control and five from the negative control groups. Feed 626 
intake was not affected by treatment. The results showed a significantly higher egg weight and egg 627 
mass production, and a better feed to egg mass ratio, in the hens fed the phytase than in the negative 628 
control hens. 629 
Table 10:  Effect of Axtra® PHY on the performance of hens from weeks 26 to 60  630 
Treatment Daily feed 
intake (g) 
Laying rate 
(%) 
Egg weight 
(g) 
Egg mass 
production 
(g/hen/day) 
Feed to egg 
mass ratio 
Negative control 116 89.0 64.7
b
 56.6
b
 2.01
a
 
300 FTU/kg 117 92.4 67.2
a
 62.2
a
 1.88
b
 
Positive control 119 91.1 66.7
a
 60.0
a
 1.97
a
 
a,b Values within one column with different superscripts are significantly different (P < 0.05). 631 
The supplementation of the diets with 250 FTU/kg feed improved phosphorus utilisation in only two 632 
trials. In the third trial, the supplementation of the diets with 300 FTU/kg improved the laying 633 
performance of the hens and the feed to egg mass ratio. 634 
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4.4. Weaned piglets 635 
4.4.1. Trial 1 636 
A balance trial was performed with a total of 20 castrated male and female weaned piglets 637 
(Talent × (Great York × Landrace)), approximately 27 days old and initial body weight of 8.5 kg).
44
 638 
During the first week post weaning, the piglets were penned in pairs and fed a commercial diet. 639 
During the experimental periods, from days 9 to 22 (period 1: 9 castrated male and 11 female weaned 640 
piglets) and from days 23 to 37 (period 2: 12 castrated male and 8 female weaned piglets) post 641 
weaning, the piglets were individually housed in pens that permitted a separate collection of faeces 642 
and urine. Feed was restricted to provide 3.2 × energy for maintenance, and water was available ad 643 
libitum over an experimental period of 28 days. Each piglet received different diets over the two 644 
periods. A total of five dietary treatments were considered, resulting in eight replicates per treatment 645 
(four per period). A basal diet, based on barley, maize and soya bean with a total phosphorus content 646 
of 0.47 % (calcium 0.64 %), was either not supplemented (negative control) or supplemented with 647 
Axtra
®
 PHY phytase to provide 250, 500 or 1 000 FTU/kg of diet (confirmed by analysis). A positive 648 
control diet was also used (total phosphorus content 0.63 %, calcium 0.71 %). Each period consisted 649 
of 10 days of adaptation to the diet and four days of collection of faeces and urine (urine collected in 650 
acid). Body weight and feed intake were recorded at days 8, 22 and 37 post weaning, and daily feed 651 
intake, daily body weight gain and feed to gain ratio were calculated for period 1 (9–22 days post 652 
weaning) and period 2 (23–37 days post weaning). Mortality was checked daily. Faecal and urine 653 
samples were collected from days 10 to 14 in both periods (i.e. days 18–22, in period 1, and days 33– 654 
37, in period 2, post weaning). Faecal apparent digestibility of dry matter, organic matter, crude 655 
protein, crude fat, ash, gross energy, calcium, phosphorus and sodium were determined using HCl- 656 
indigestible ash as an external marker. Urine was analysed for energy, nitrogen, calcium and 657 
phosphorus. The retention of energy, nitrogen (data not shown), calcium and phosphorus was 658 
calculated. An ANOVA was carried out with the data and the group means were compared with a 659 
Tukey test. 660 
No pig died during the experiment. Phytase supplementation from 250 FTU/kg significantly increased 661 
faecal digestibility of ash, calcium and phosphorus (data not shown), as well as calcium and 662 
phosphorus retention (Table 11). Apparent faecal digestibility of dry matter was significantly 663 
increased at 500 FTU/kg. Apparent faecal digestibility and retention of the other nutrients tested, as 664 
well as the metabolisable energy content of the diets, were not affected by dietary treatments. 665 
Table 11:  Effect of Axtra® PHY on the retention of calcium and phosphorus  666 
Treatment Phosphorus (%) Calcium (%) 
Negative Control  40.7
d
 49.4
c
 
250 FTU/kg 56.2
b
 65.9
ab
 
500 FTU/kg 60.0
ab
 68.5
ab
 
1 000 FTU/kg 64.5
a
 72.7
a
 
Positive control 50.0
c
 59.7
b
 
a,b,c,d Values within one column with different superscripts are significantly different (P < 0.05). 667 
4.4.2. Trial 2 668 
A balance trial was performed with a total of 54 castrated male weaned piglets (PIC commercial 669 
breed, approximately 33 days old and initial body weight of 9.8 kg) housed in individual pens, before 670 
and after moving to digestibility crates, and allocated to six dietary treatments (nine pigs per 671 
treatment).
45
 A basal diet, based on maize and soya bean meal with a total phosphorus content of 672 
0.45 % (calcium 0.68 %), was either not supplemented (negative control) or supplemented with Axtra
®
 673 
PHY phytase to provide 250, 500, 1 000 or 2 000 FTU/kg of diet (confirmed by analysis). A positive 674 
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control group was also considered (total phosphorus content 0.68 %, calcium 0.89 %). The overall 675 
experimental period lasted 42 days and was conducted in three runs (14 days for each run). Each run 676 
(period) consisted of 10 days of adaptation to the diet and four days of collection of faeces and urine 677 
(which were separated). Test diets (pelleted feed) were restricted to provide 3 × metabolisable energy 678 
for maintenance, and water was available ad libitum. Feed intake and body weight were recorded at 679 
days 1 and 14 of each run, and daily feed intake, daily weight gain and feed-to-gain ratio were 680 
calculated for each run. Mortality was checked daily. Faecal apparent digestibility of dry matter, crude 681 
protein, gross energy, calcium and phosphorus were determined using HCl-acid indigestible ash as an 682 
external marker. Urine was analysed for gross energy, nitrogen, calcium and phosphorus. Retention of 683 
gross energy, nitrogen, calcium and phosphorus was calculated. An ANOVA was carried out with the 684 
data and the group means were compared with a Tukey test. 685 
No pig died during the experiment. Phytase supplementation from 250 FTU/kg significantly increased 686 
apparent faecal digestibility (data not shown) and retention of phosphorus compared with the negative 687 
control diet (Table 12). Significant improvements with regard to calcium digestibility, at the dose of 688 
1000 FTU/kg (data not shown), and retention, at the dose of 500 FTU/kg feed, were found. Apparent 689 
faecal digestibility of dry matter, crude protein and gross energy, and retention of nitrogen and gross 690 
energy, were not affected by dietary treatments (data not shown). 691 
Table 12:  Effect of Axtra® PHY on the retention of phosphorus and calcium  692 
Treatment Phosphorus (%) Calcium (%) 
Negative control  51.5
d
 39.8
d
 
250 FTU/kg 59.4
c
 41.2
cd
 
500 FTU/kg 62.8
bc
 49.6
bc
 
1 000 FTU/kg 76.3
a
 60.2
a
 
2 000 FTU/kg 75.5
a
 60.2
a
 
Positive control 68.3
b
 58.2
ab
 
a,b,c,d Values within one column with different superscripts are significantly different (P < 0.05). 693 
4.4.3. Trial 3 694 
A balance trial was performed with a total of 22 castrated male and 18 female weaned piglets (Great 695 
York × Landrace mated with Tempo commercial hybrid boar, approximately 35–42 days old with an 696 
initial body weight of 8.1 kg).
46
 The study was performed in two runs; 20 piglets participated in run 1 697 
and 20 piglets were used in run 2. During the first 12 days post weaning, the piglets were penned in 698 
litter groups and fed a commercial diet. On day 13 post weaning, piglets were moved to individual 699 
digestibility crates and allocated to four dietary treatments (in total, 10 piglets were used per 700 
treatment). Feed was restricted to provide 3.5 × energy for maintenance (at day 19 post weaning) and 701 
water was available ad libitum over an experimental period of 12 days. Pigs were fed a weaner diet 702 
(pelleted feed) from day 13 until day 24 post weaning. The diets were produced as pellets but, in order 703 
to ensure a sufficient feed intake, the pellets were mixed with water, at a water-to-pellet ratio of 3:1, 704 
just before feeding. The weaner diet, based on barley, maize and soya bean meal with a total 705 
phosphorus content of 0.45 % (calcium 0.60 %), was either not supplemented or supplemented with 706 
Axtra
®
 PHY phytase to provide 250 or 500 FTU/kg of diet (confirmed by analysis). A positive control 707 
diet was also considered (total phosphorus content 0.63 %, calcium 0.70 %). The experiment consisted 708 
of seven days of adaptation to the diet and five days (day 19 until day 24 post weaning) of collection 709 
of faeces and urine (urine collected in acid). Feed intake and body weight were recorded at days 12 710 
and 24 post weaning, and daily feed intake, daily weight gain and feed to gain ratio were calculated. 711 
Mortality was checked daily. Faecal apparent digestibility of dry matter, organic matter, crude protein, 712 
crude fat, ash, gross energy, calcium, phosphorus and sodium were determined using HCl-insoluble 713 
ash as an external marker. Urine was analysed for nitrogen, calcium and phosphorus, and retention of 714 
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nitrogen, calcium and phosphorus was calculated. An ANOVA was carried out with the data and the 715 
group means were compared with a Tukey test 716 
No pig died during the experiment. Phytase supplementation significantly increased faecal digestibility 717 
of ash, calcium and phosphorus (data not shown), as well as calcium and phosphorus retention at the 718 
dose of 250 FTU/kg or above (Table 13). Faecal digestibility of dry matter, crude protein and gross 719 
energy, and retention of nitrogen, was not affected by dietary treatments (data not shown). 720 
Table 13:  Effect of Axtra® PHY on the retention of phosphorus and calcium 721 
Treatment Phosphorus (%) Calcium (%) 
Negative Control  29.8
c
 43.1
b
 
250 FTU/kg 59.1
ab
 61.1
a
 
500 FTU/kg 61.6
a
 61.6
a
 
Positive Control 57.0
b
 47.5
b
 
a,b,c,d Values within one column with different superscripts are significantly different (P < 0.05). 722 
The results of the three short-term trials carried out with weaned piglets showed that the 723 
supplementation of the diets with 250 FTU/kg feed increased the phosphorus retention in weaned 724 
piglets. 725 
4.5. Pigs for fattening 726 
A total of six trials were assessed, one
47
 of which was not considered further in the assessment because 727 
only digestibility was measured. Therefore, for pigs for fattening, four short-term were considered and 728 
one long-term efficacy studies. 729 
4.5.1. Trial 1 730 
A balance trial was performed with a total of 30 male pigs (Landrace × Piétrain, approximately 105 731 
days old and initial body weight of 48 kg) housed individually and allocated to five dietary 732 
treatments.
48
 A basal diet, based on barley, wheat and soya bean with a total phosphorus content of 733 
0.38 % (calcium 0.60 %), was either not supplemented (negative control) or supplemented with 734 
Axtra
®
PHY phytase to provide 250, 1 000 and 2 000 FTU/kg feed (confirmed by analysis). A positive 735 
control was also considered (total phosphorus content 0.53 %; calcium 0.68 %). The balance study 736 
was conducted seven times, using 10 individually caged animals in each run (20 pigs used two times 737 
and 10 used three times). Each run consisted of 10 days of adaptation to the diet and three days of 738 
collection. Between runs, the animals received a commercial diet for one week. Animals changed diets 739 
when involved in a second/third round. Pigs were housed individually in crates for a three-day 740 
adjustment period prior to a three-day collection period of faeces and urine (urine collected in acid). 741 
The overall experimental period lasted 63 days. Test diets (mashed feed) were fed restrictively to 742 
provide 2.2 × metabolisable energy for maintenance, and water was available ad libitum. Mortality 743 
was checked daily. Faecal apparent digestibility of dry matter, nitrogen, gross energy, calcium and 744 
phosphorus were determined, using three methods (total faeces collection method and methods using 745 
titanium dioxide or HCl-indigestible ash as external markers). Urine was analysed for gross energy, 746 
nitrogen, calcium and phosphorus. Retention of nitrogen, gross energy, calcium and phosphorus were 747 
also determined. An ANOVA was carried out with the data and the group means were compared with 748 
a Tukey test. 749 
No pig died during the experiment, but five pigs were removed from the study mainly because of 750 
respiratory problems. In total, the number of observations per treatment were 13, 13, 13, 12 and 14 for 751 
the negative control, 250, 1 000 and 2 000 FTU/kg feed and positive control groups, respectively. 752 
Phytase addition from 250 FTU/kg feed significantly increased faecal digestibility of calcium, 753 
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phosphorus and dry matter (data not shown), as well as calcium and phosphorus retention (Table 14). 754 
Faecal digestibility and retention of nitrogen and gross energy were not affected by dietary treatments 755 
(data not shown). 756 
Table 14:  Effect of Axtra® PHY on the retention of phosphorus and calcium 757 
Treatment Phosphorus (%) Calcium (%) 
Negative control 35.0
d
 43.8
c
 
250 FTU/kg 54.0
bc
 59.2
ab
 
1 000 FTU/kg 62.3
ab
 65.3
a
 
2 000 FTU/kg 64.6
a
 67.5
a
 
Positive control 45.1
c
 54.7
b
 
a,b,c,d Values within one column with different superscripts are significantly different (P < 0.05). 758 
4.5.2. Trial 2 759 
A balance trial was performed with a total of 45 castrated male pigs (Camborough 22 or Line 760 
22 × Terminal Sire Boars, approximately 79 days old and initial body weight of 43 kg) housed 761 
individually and allocated to five dietary treatments (nine pigs per treatment).
49
 A basal diet, based on 762 
maize and soya bean meal with a total phosphorus content of 0.59 % (calcium 0.57 %), was either not 763 
supplemented or supplemented with Axtra
®
 PHY to provide 250, 500 or 2 000 FTU/kg feed 764 
(confirmed by analysis) A positive control group was also considered (total phosphorus content of 765 
0.71 %; calcium 0.72 %). The overall experimental period lasted 42 days and was conducted in three 766 
runs (14 days for each run). Each run consisted of 10 days of adaptation to the diet and four days of 767 
collection of faeces and urine (separated). Test diets (mashed feed) were fed restrictively to provide 768 
3 × metabolisable energy for maintenance, and water was available ad libitum. Feed intake and body 769 
weight were recorded at days 1 and 14 of each run, and average feed intake, daily weight gain and 770 
feed to gain ratio were calculated for each run. Mortality was checked daily. Faecal apparent 771 
digestibility of dry matter, crude protein, gross energy, calcium and phosphorus were determined using 772 
HCl-insoluble ash as an external marker. Retention of nitrogen, gross energy, calcium and phosphorus 773 
were also calculated. An ANOVA was carried out with the data and the group means were compared 774 
with an LSD test. 775 
No pig died during the experiment, but one pig, from the negative control group, was removed from 776 
the study because of severe lameness. Phytase supplementation from 250 FTU/kg feed increased 777 
significantly faecal digestibility of calcium and phosphorus (data not shown), and calcium retention, 778 
but phosphorus retention increased only from the dose of 500 FTU/kg (Table 15). Faecal digestibility 779 
of dry matter, crude protein, gross energy, and retention of gross energy, was not affected by dietary 780 
treatments (data not shown). 781 
Table 15:  Effect of Axtra® PHY on the retention of phosphorus and calcium  782 
Treatment Phosphorus (%) Calcium (%) 
Negative control 36.9
cd
 51.4
c
 
250 FTU/kg 41.7
bc
 62.4
b
 
500 FTU/kg  48.6
a
 68.5
a
 
2 000 FTU/kg 46.8
ab
 67.8
a
 
Positive control 34.0
d
 52.8
c
 
a,b,c,d Values within one column with different superscripts are significantly different (P < 0.05). 783 
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4.5.3. Trial 3 784 
A balance trial was performed with a total of 48 male pigs (Landrace × Piétrain, approximately 98– 785 
112 days old and initial body weight of 61.6 kg) housed in growing pens (three pigs/pen), before and 786 
after moving to individual digestibility crates, and allocated to four dietary treatments (12 pigs per 787 
treatment).
50
 A basal diet, based on barley, wheat, maize and soya bean meal with a total phosphorus 788 
content of 0.46 % (calcium 0.46 %), was either not supplemented (negative control) or supplemented 789 
with Axtra
®
 PHY to provide 250 or 500 FTU/kg of diet (confirmed by analysis). A positive control 790 
diet was also considered (total phosphorus content of 0.65 %, calcium 0.55 %). The experiment was 791 
performed in four runs. Each run (period) consisted of 10 days of adaptation to the diet and three days 792 
of collection of faeces and urine (which were separated; urine collected in acid). Test diets (pelleted 793 
feed) were fed on ad libitum basis during adaptation in growing pens and restricted to provide 794 
2.2 × metabolisable energy for maintenance when present in the metabolic pens (and mixed with water 795 
at a water-to-pellet ratio of 1:2); water was available ad libitum. Pigs were weighed and feed intake 796 
was monitored throughout the study. Faecal apparent digestibility of dry matter, nitrogen, gross 797 
energy, ash, calcium and phosphorus was determined, using three methods (total faeces collection 798 
method and methods using titanium dioxide and HCl-indigestible ash as external markers). Retention 799 
of gross energy, nitrogen, calcium and phosphorus were also determined. An ANOVA was carried out 800 
with the data and the group means were compared with a Tukey test. 801 
No pig died during the experiment. Phytase addition from the dose of 250 FTU/kg feed significantly 802 
increased faecal digestibility of phosphorus, ash and calcium (data not shown), as well as phosphorus 803 
retention (Table 16). Retention of nitrogen and gross energy were not affected by dietary treatments 804 
(data not shown). 805 
Table 16:  Effect of Axtra® PHY on the retention of phosphorus and calcium  806 
Treatment Phosphorus (%) Calcium (%) 
Negative control 33.6
c
 33.8
b
 
250 FTU/kg 50.2
ab
 46.7
ab
 
500 FTU/kg 57.9
a
 56.2
a
 
Positive control 42.3
bc
 50.1
a
 
a,b,c Values within one column for the same study with different superscripts are significantly different (P < 0.05). 807 
4.5.4. Trial 4 808 
A balance trial was performed with a total of eight castrated male pigs (Topigs × Piétrain, initial body 809 
weight of 41 kg).
51
 The overall experimental period lasted 35 days (seven-day adaptation period and 810 
28-day digestibility study) and followed a 4 × 4 Latin-square design (four periods; eight pigs per 811 
treatment). Each period consisted of three days of adaptation to the diet and four days of collection of 812 
faeces and urine (separated, total faeces and urine collection). Test diets (mashed feed) were fed 813 
restrictively to provide 2.8 × metabolisable energy for maintenance, and water was available ad 814 
libitum. A basal diet, based on barley, wheat, maize and soya bean meal with a total phosphorus 815 
content of 0.36 % (calcium 0.60 %), was either not supplemented (negative control) or supplemented 816 
with Axtra
®
 PHY phytase to provide 250 or 500 FTU/kg feed (confirmed by analysis). A positive 817 
control diet was also considered (total phosphorus content of 0.48 %, calcium 0.76 %). Pigs were 818 
weighed at the start of the study and every week thereafter. Faecal digestibility of dry matter, calcium 819 
and phosphorus were determined, using two methods (total faeces collection method and a method 820 
using titanium dioxide as a marker). The retention of phosphorus was also determined. An ANOVA 821 
was carried out with the data and the group means were compared with a Tukey test. 822 
No pig died during the experiment. Phytase addition from 250 FTU/kg feed significantly increased 823 
faecal digestibility of calcium, phosphorus and dry matter (data not shown), as well as phosphorus 824 
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retention (40.6, 48.0, 59.9 and 46.5 % for the negative control, 250 FTU/kg, 500 FTU/kg and positive 825 
control groups, respectively). 826 
4.5.5. Trial 5 827 
A performance study with measurements of bone mineralisation was conducted with a total of 36 male 828 
and 36 female Piétrain × (Landrace × Duroc) pigs (initial body weight of 30.7 kg) individually housed 829 
in 72 pens and allocated to four dietary treatments (18 replicates per treatment).
52
 Two grower diets 830 
and one finisher diet, based on barley, wheat, maize and soya bean meal with a total phosphorus 831 
content of 0.43, 0.49 and 0.46 %, respectively (calcium 0.60, 0.55 and 0.49 %), were either not 832 
supplemented (negative control) or supplemented with Axtra
®
PHY to provide 250 or 500 FTU/kg feed 833 
(confirmed by analysis). A positive control was also considered (phosphorus contents of 0.55, 0.54 834 
and 0.50 %, respectively, and calcium contents of 0.70, 0.65 and 0.60 %, respectively). Feed and water 835 
were available ad libitum over an experimental period of 96 days. Pigs were fed a grower diet 836 
(pelleted feed) from day 1 until day 35 (phase 1), a grower diet (pelleted feed) from day 36 until day 837 
70 (phase 2), and a finisher diet (pelleted feed) from day 71 until day 96 (phase 3) of the experiment. 838 
Feed intake and body weight were measured at days 0, 35, 70 and 96, and daily feed intake, daily 839 
weight gain and feed to gain ratio were calculated for phase 1 (days 1–35 of the experiment), phase 2 840 
(days 36–70 of the experiment), phase 3 (days 71–96 of the experiment) and the overall period. Health 841 
status and mortality were checked daily. In addition, on day 96 of the experiment, all pigs were 842 
slaughtered for the evaluation of carcass characteristics and bone mineralisation (both metacarpi were 843 
extracted). Bones were defatted, dried, weighed and ashed and then analysed for dry matter, ash, 844 
calcium and phosphorus contents. Data were statistically analysed by ANOVA and the comparison of 845 
the means was performed using a Tukey test. 846 
No pig died during the experiment. Phytase diet supplementation at 250 FTU/kg resulted in a 847 
significant improvement in feed to gain ratio (Table 17), but the effect was not found at 500 FTU/kg 848 
feed. 849 
Table 17:  Effect of Axtra®PHY on the performance of pigs for fattening 850 
Treatment Daily feed intake 
(kg) 
Final body 
weight (kg) 
Average daily gain (kg) Feed to gain 
ratio 
Negative control 2.05 100.2
b
 0.72
b
 2.84
a
 
250 FTU/kg 2.09 107.2
ab
 0.80
ab
 2.63
b
 
500 FTU/kg 2.12 106.6
ab
 0.79
ab
 2.70
ab
 
Positive control 2.16 109.9
a
 0.82
a
 2.64
b
 
a,b Values within one column for the same study with different superscripts are significantly different (P < 0.05). 851 
In three short-term trials with pigs for fattening, the supplementation of the diets with Axtra
®
 PHY 852 
phytase at a dose of 250 FTU/kg feed increased phosphorus retention. 853 
4.6. Sows for reproduction 854 
4.6.1. Trial 1 855 
A total of 40 gestating sows (Crossbred) were housed in individual pens and, after equal distribution 856 
relative to parity (2–8), were allocated to five dietary treatments (eight sows per treatment).53 Water 857 
was available ad libitum over the experimental period (at the start of the experiment all sows were 858 
between day 70 and day 100 of gestation; in total, 17 days of the experiment were during gestation). 859 
Sows were fed a restricted gestation diet (pelleted feed). The gestation diet, based on maize, sunflower 860 
and rapeseed with a total phosphorus content of 0.44 % (calcium 0.52 %), was either not 861 
supplemented (negative control) or supplemented with Axtra
®
 PHY phytase to provide 250, 1 000 or 862 
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2 000 FTU/kg feed (confirmed by analysis). A positive control group was also considered (with a total 863 
phosphorus content of 0.62 %; calcium 0.68 %). The experiment consisted of 14 days of adaptation to 864 
the diet and three days (day 15 until day 17) of collection of faeces. The sows’ weights were measured 865 
at only the start of the experiment and feed intake was 3.2 kg/day throughout the experiment. Faecal 866 
digestibility of dry matter, organic matter, crude protein, ash, gross energy, calcium (data not shown) 867 
and phosphorus were determined, using HCl-indigestible ash as an external marker. An ANOVA was 868 
performed with the data and the group means were compared with a Tukey test. 869 
None of the sows died during the experiment. Phytase addition from the dose of 250 FTU/kg 870 
significantly increased faecal digestibility of phosphorus (24.4, 36.5, 41.0, 39.5 and 32.7 % for the 871 
negative control, 250 FTU/kg, 1 000 FTU/kg, 2 000 FTU/kg and positive control groups, 872 
respectively). 873 
4.6.2. Trial 2 874 
A total of 56 lactating sows (Crossbred) were housed in individual pens and, after equal distribution 875 
relative to parity (2–6), were allocated to seven dietary treatments (eight sows per treatment).54 Water 876 
was available ad libitum over the experimental period (from day 4 until day 21 post farrowing; in total, 877 
17 days of the experiment were during lactation). Sows were fed a restricted lactation diet (pelleted 878 
feed) from day 4 until the end of the experiment. A lactation diet, based on maize and soya bean meal 879 
with a total phosphorus content of 0.45 % (calcium 0.55 %), was either not supplemented (negative 880 
control) or supplemented with Axtra
®
 PHY phytase to provide 250, 500, 750, 1 000 or 2 000 FTU/kg 881 
feed (confirmed by analysis). A positive control was also considered (total phosphorus content of 882 
0.63 %). The experiment consisted of 14 days of adaptation to the diet and three days of collection of 883 
faeces. Sow body weight was measured at day 108 of gestation and at weaning (six days after the end 884 
of faecal collection). Feed intakes were recorded daily. For each sow, the number of piglets born (live 885 
and stillborn) and the number of piglets at the start of the experiment and at weaning, was recorded. 886 
Faecal digestibility of dry matter, organic matter, crude protein, ash, gross energy, calcium and 887 
phosphorus were determined, using HCl-indigestible ash as an external marker. An ANOVA was 888 
performed with the data and group means were compared with a Tukey test. 889 
None of the sows died during the experiment. There were no significant treatment-related effects on 890 
sows’ body weight or feed intake, or parameters related to the piglet litters. Phytase addition from 891 
250 FTU/kg feed increased apparent faecal digestibility of phosphorus (30.1, 44.6, 48.9, 49.1, 50.4, 892 
52.7 and 39.0 % for the negative control, 250 FTU/kg, 500 FTU/kg, 750 FTU/kg, 1 000 FTU/kg, 893 
2 000 FTU/kg and positive control groups, respectively). 894 
4.6.3. Trial 3 895 
A total of 41 lactating sows (Yorkshire or Yorkshire × Landrace crossbred sows), from two farrowing 896 
groups (17 in March and 24 in May), were housed in individual pens and, after equal distribution 897 
relative to parity (1–6, average of 2.24), were allocated to three dietary treatments (13/15 sows).55 A 898 
lactation diet, based on maize and soya bean meal with a total phosphorus content of 0.46 % (calcium 899 
0.55 %), was either not supplemented (negative control) or supplemented with Axtra
®
 PHY phytase to 900 
provide 250 FTU/kg of diet (confirmed by analysis). A positive control diet was also considered (total 901 
phosphorus content 0.63 %, calcium 0.75 %). Feed and water were available ad libitum over the 902 
experimental period (from day 4 until day 19 post farrowing). The experiment consisted of 13 days of 903 
adaptation to the diet and three days of collection of faeces. Sow body weight was measured at 904 
farrowing, at day 4 and day 19 post farrowing, and at weaning. Feed intake was recorded daily. For 905 
each sow, the number of piglets born (live and stillborn), the number of piglets at days 4 and 19, and 906 
the number at weaning were recorded. In addition, piglet weight (at birth, at days 4 and 19 of age, and 907 
at weaning), mortality and average daily weight gain during lactation were recorded. Faecal 908 
digestibility of dry matter, organic matter and nitrogen, crude fat, neutral detergent fibre, ash, gross 909 
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energy, calcium and phosphorus were determined using titanium dioxide as an external marker. An 910 
ANOVA was performed with the data and group means were compared with a Tukey test. 911 
None of the sows died during the experiment. There were no significant treatment-related effects on 912 
sow body weight or feed intake, or on parameters related to piglet litters. Phytase addition at 913 
250 FTU/kg feed significantly increased faecal digestibility of phosphorus (37.3, 47.2 and 42.7 % for 914 
the negative control, 250 FTU/kg and positive control groups, respectively). 915 
The supplementation of the diets with 250 FTU/kg feed resulted in a higher faecal apparent 916 
phosphorus digestibility in sows (either lactating or gestating). 917 
4.7. Conclusions on the efficacy 918 
Based on the results obtained in the efficacy trials provided, the Panel concludes that the additive is 919 
efficacious at the dose of 250 FTU/kg feed in chickens and turkeys for fattening, weaned piglets, pigs 920 
for fattening and sows. The FEEDAP Panel notes that, for laying hens, two studies showed a 921 
significant effect at 250 FTU/kg and one showed an effect at 300 FTU/kg (the lowest dose tested in 922 
the latter study). Considering that efficacy has been demonstrated at 250 FTU/kg for all the other 923 
species/categories examined and that the difference between 250 and 300 FTU/kg is small, the Panel 924 
concludes that for laying hens the effective dose can be established at 250 FTU/kg. 925 
The Panel considers that the conclusions on efficacy can be extended to chickens reared for laying, to 926 
turkeys reared for breeding and to turkeys for breeding purposes. The mode of action of phytases is 927 
well known and is considered to be similar within avian species: therefore, these conclusions can also 928 
be extrapolated to minor poultry species and minor porcine species at the same dose. 929 
5. Post-market monitoring 930 
The FEEDAP Panel considers that there is no need for specific requirements for a post-market 931 
monitoring plan other than those established in the Feed Hygiene Regulation
56
 and Good 932 
Manufacturing Practice. 933 
CONCLUSIONS 934 
Axtra
®
 PHY 15 000 L does not give rise to safety concerns with regard to the genetic modification of 935 
the production strain. Neither the production strain nor its recombinant DNA was detected in the final 936 
product obtained from the production strain. 937 
The additive is safe for chickens and turkeys for fattening, laying hens, weaned piglets and sows at the 938 
maximum recommended dose of 2 000 FTU/kg feed. The Panel considers that the conclusions can be 939 
extended to chickens reared for laying and turkeys reared for breeding, to turkeys for breeding 940 
purposes and to pigs for fattening, and can be extrapolated to minor poultry and porcine species at the 941 
same maximum dose. 942 
The use of Axtra
®
 PHY 15 000 L as a feed additive gives rise to no concerns for consumers. 943 
The additive is not considered a dermal sensitiser but should be considered as a potential irritant to 944 
skin, eyes and the respiratory tract. Owing to the proteinaceous nature of its active substance, the 945 
additive is considered a potential respiratory sensitiser. 946 
The use of Axtra
®
PHY 15 000 L as a feed additive poses no risks to the environment. 947 
Axtra
®
PHY 15 000 L is efficacious in chickens and turkeys for fattening, laying hens, piglets, pigs for 948 
fattening and sows at the dose of 250 FTU/kg feed. These conclusions can be extended to chickens 949 
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reared for laying, to turkeys reared for breeding and to turkeys for breeding purposes, and extrapolated 950 
to minor poultry species and minor porcine species at the dose of 250 FTU/kg. 951 
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ANNEX 974 
Annex A.  Executive Summary of the Evaluation Report of the European Union Reference 975 
Laboratory for Feed Additives on the Method(s) of Analysis for Axtra
®
PHY 15 000L
57
 976 
In the current application authorisation is sought under article 4(1) for Axtra® Phy 15000L, under the 977 
category/functional 4(a) “zootechnical additives”/”digestibility enhancers” according to the 978 
classification system of Annex I of Regulation (EC) No 1831/2003. Specifically, authorisation is 979 
sought for the use of the feed additive for chickens and turkeys for fattening, chickens reared for 980 
laying, turkeys reared for breeding, turkeys for breeding purposes, laying hens, minor avian species, 981 
weaned piglets, pigs for fattening, sows for reproduction, and minor porcine species. The active agent 982 
of Axtra® Phy 15000L is 6-phytase (EC 3.1.3.26), produced by fermentation of Trichoderma reesei. 983 
According to the Applicant, Axtra® Phy 15000L is a liquid preparation with a guaranteed minimum 984 
enzyme activity of 15000 U/g. It is intended to be used in premixtures and/or complete feedingstuffs 985 
to obtain 6-phytase activities ranging from 250 to 2000 U/kg feedingstuffs. The Applicant uses the 986 
international phytase unit defined in the EN ISO 30024, where “one phytase unit (U) is the amount of 987 
enzyme which releases one micromole of inorganic phosphate from sodium phytate per minute at pH 988 
5.5 and 37°C”. 989 
For the determination of phytase in the feed additive, premixtures and feedingstuffs, the Applicant 990 
submitted colorimetric methods derived from the EN ISO 30024 standard method. Phytase is 991 
incubated with sodium phytate, resulting in the release of inorganic phosphate and forming a yellow 992 
complex with an acidic molybdate/vanadate reagent. Based on the experimental data available, the 993 
EURL recommends for official control the in-house validated and further verified method for the 994 
quantification of phytase activity in the feed additive and the EN ISO 30024 standard method for the 995 
quantification of phytase activity in premixtures and feedingstuffs. 996 
Further testing or validation of the methods to be performed through the consortium of National 997 
Reference Laboratories as specified by Article 10 (Commission Regulation (EC) No 378/2005) is not 998 
considered necessary. 999 
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